THE TRILLION-DOLLAR PRE-IPO

1 1 THE TRILLION-DOLLAR PRE-IPOBy Teeka Tiwari, Michael Zappy Zapolin, and William and time again, we ve seen the impact of being early and being right on a massive, game-changing in the early 2000s, when the internet was in its early stages, few investors recognized its potential. But those who did and bet on the right companies reaped the instance, Teeka s first TRILLION-DOLLAR trade was in 2003 when he identified Apple, the world s first TRILLION-DOLLAR company. Buying Apple at his recommended price could have turned $1,000 into $364, second TRILLION-DOLLAR trade happened when he found cryptocurrencies in 2016 today worth over $1 trillion. If you had listened to just one of Teeka s crypto you could have turned that same $1,000 into $ point is, when you ve identified an unstoppable trend, it s not enough to pick the right companies involved in you also have to get into them at the right time.

2 THE TRILLION-DOLLAR PRE-IPOBy Teeka Tiwari, Michael Zappy Zapolin, and William MikulaTeeka s Note Friends, welcome to Palm Beach Special Opportunities. As you know, our goal in this service is to find TRILLION-DOLLAR trends in their early stages and help position you in the right companies to ride those trends to life-changing gains. Our motto is: Be early, be right. The first trend we re following is the psychedelic- and plant-based medicine industry. And in our TRILLION-DOLLAR Trade Portfolio special report, we ve unearthed five small-cap stocks to play this trend. In this special bonus for charter members of Special Ops, we re also recommending the first PRE-IPO we ve ever seen in the psychedelic space. If you follow my PRE-IPO research, you know this could potentially be the type of deal that has made fortunes for early-stage investors.

3 For instance, people who got PRE-IPO shares had the chance to make 36,000% in 110,000% in and 121,000% in , my team of Michael Zappy Zapolin and William Mikula explain why they believe this PRE-IPO company represents the chance to invest in the world s next pharma giant like Pfizer, Merck, or , let s turn it over to William and here s a secret the elite don t want you to know: Many of the results we shared above could be even if Wall Street hadn t rigged the game against everyday see, the biggest stock market gains often come when an investor gets in before a company goes public. For example, if you d invested in Google after it first went public, you d be sitting on a 4,750% gain right now enough to turn every $1,000 into $48, say you realized that social media was poised to reshape the internet as we know it and bought shares of Facebook when it IPO d.

4 You could have sold its shares for a peak gain of 813%.. turning $1,000 into $9, terrible returns. But nothing like the six-digit percentage returns PRE-IPO investors could ve made. The issue is until recently it was nearly impossible for Main Street investors to get involved before a company went public. This left this lucrative market to Wall Street fat cats and Silicon Valley insiders. But that all changed in 2012. That s when Congress passed the JOBS Act into law. However, it took the slow-moving bureaucracy six more years to adopt the final other things, the JOBS Act contained a provision allowing non-accredited investors (those with a net worth of less than $1 million) to get into deals like the Wall Street elite do. This provision created Regulation A+ deals. And they re a game A+ deals allow private companies to raise money from accredited and non-accredited investors.

5 Until recently, Wall Street and insiders had almost exclusive access to these deals. But now, Main Street can finally invest in private placements, , we re turning the We ve already helped many of our subscribers take advantage of these PRE-IPO deals in our Palm Beach Venture service. So when we first started researching the psychedelics space, we knew there would be similar opportunities if our team dug deep , these PRE-IPO deals are rarer and riskier than our small- and micro-cap stock picks. After all, the Securities and Exchange Commission (SEC) and other regulators are still getting comfortable with the industry in general. Plus, many of these treatments are still in their trial phases. Some might not see approval for many months, if at all, as states roll out phases of legalization. Or the company could never have a go-public or buyout event.

6 So we recommend no more than a minimum investment (around $500) if you re a smaller investor, and no more than you can afford to see go to zero if you re a larger investor. Just like getting in early on Facebook and Google, we believe the PRE-IPO gains in this space can be life changing. That s why all it takes is a small starting stake to see incredible gains. You can make outsized gains without putting your lifestyle at this special report, we ve found a PRE-IPO deal that represents the chance to invest in the world s next pharma giant like Pfizer, Merck, or re releasing this first-of-its-kind PRE-IPO deal to charter members of Palm Beach Special You re the first to get it. So you have multiple ways of being early and being right on Teeka s third TRILLION-DOLLAR trade. , we don t plan to cover another deal like this in our service.

7 This deal has a time limit and is limited to how much money it can raise. So, let s get to this unique opportunity while we still have the First psychedelics PRE-IPO Deal of Its KindThe PRE-IPO company we re recommending is is the first qualified PRE-IPO offering we know of that develops products from all-natural plant-based substances. It s qualified to raise up to $ million. Each PRE-IPO share costs $ And the minimum investment is $ for 101 shares. is focused on disrupting the $429 billion global nutraceutical As well as the traditional medical market that treats mental health issues like anxiety, depression, and ADHD with outdated and potentially addictive pills. What Are Nutraceuticals? Nutraceuticals describe any product made from food sources that come with extra health benefits. They can be used to prevent and treat a wide range of medical problems, including cardiovascular diseases, eye disorders, obesity, and mental health.

8 They re largely unregulated by the Food and Drug Administration (FDA), as they re in the same category as dietary supplements and food additives. Examples include green tea, ginseng, probiotics, and fish is using the proceeds from this offering to speed up development and distribution of the company s medicinal and functional mushroom product lines. (You can read more about mushroom-derived psychedelic compounds in our Third TRILLION-DOLLAR Trade Portfolio report.)As we ll show you below, based on our research, if this company captures just 1% of its addressable we could see shares catapulting from their current PRE-IPO price of $ per share to $384. That s a 7,774% gain enough to turn a small $494 starting stake (the minimum in this deal) into a $38,403 windfall. To understand the scope of this deal, let s run through our proprietary SPOR system, which stands for Strategy, People, Opportunity, and Return potential.

9 This helps us narrow down which opportunities hold the highest potential in this burgeoning space.(You can read more about our SPOR strategy in the Palm Beach Special Opportunities Manifesto.)Important Note Neither the Palm Beach Research Group nor its affiliates receive compensation for bringing this deal to you. As publishers of financial information, we make general recommendations based on our own analysis. We do not offer this reason, our Palm Beach Special Ops customer service team will not be able to assist you with this deal. Please contact directly for all investment core strategy is to use all-natural botanical material to disrupt two core markets: nutraceuticals and traditional pharma. All told, this is a massive combined addressable market of $604 billion. the company estimates 700 million people could benefit from its products.

10 They re designed to prevent, reverse, and manage chronic health disorders like anxiety, depression, and ADHD. To do so, Ei has a two-pronged approach. First, it plans to get sales rolling in through nutraceuticals. Since these are mainly packaged food products, nutraceuticals are easy to get on They don t require millions of dollars and years of clinical trials to develop. And nutraceuticals start producing immediate cash flow. Second, at the same time, it ll submit drugs into the traditional FDA pipeline approval process. FDA-approved drugs offer patent protection and massive blue-sky to deliver these treatments, Ei will use traditional sales channels as well as telemedicine and virtual medical treatments through licensed medical professionals. This market segment has exploded on the heels of COVID-19 as people were forced to adapt to appointments over the phone or online.